Filing Flows

Filing Flows › Protalix BioTherapeutics (PLX) › Next earnings date

Protalix BioTherapeutics (PLX) earnings on Nov 10, 2026: what to expect

Protalix BioTherapeutics (PLX) is expected to report earnings on Nov 10, 2026, in 2 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.02 (−$0.05 to $0.01, 2 estimates) on revenue of $12.3M, against $0.03 and $17.9M a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 61% chance of beating next time.

Report dateNov 10, 2026
Days to go2
EPS estimate−$0.02
Revenue estimate$12.3M
Beat rate50%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Protalix BioTherapeutics: revenue lines, growth year over year, Q2 2026Protalix BioTherapeutics: revenue lines, growth year over year, Q2 2026Revenue+27%GOODS+28%LICENSE AND R&D SERVICES-69%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS $0.06 on revenue of $42.2M, against the analysts' −$0.02.

The last report

Protalix BioTherapeutics reported revenue of $19.9M for the second quarter 2026 (+27% Y/Y), net earnings $3.8M: GOODS $19.8M, LICENSE AND R&D SERVICES $68K. How it makes money → · Every quarter →

Protalix BioTherapeutics: EPS against the estimate, last 4 reportsProtalix BioTherapeutics: EPS against the estimate, last 4 reportsEstimateReported$0.06$0.03Nov 25$0.01−$0.07Mar 26−$0.01$0.22May 26−$0.01$0.05Aug 26
Latest (Aug 26): Estimate −$0.01, Reported $0.05.

Protalix BioTherapeutics' latest quarter

Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.

Questions

When does PLX report earnings?

Protalix BioTherapeutics is expected to report on Nov 10, 2026.

What are analysts expecting from Protalix BioTherapeutics?

EPS of −$0.02 and revenue of $12.3M for the quarter.

Does Protalix BioTherapeutics usually beat earnings?

It beat the consensus EPS estimate in 50% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.